GX 03
Alternative Names: GX-03Latest Information Update: 28 Feb 2023
At a glance
- Originator Turn Therapeutics
- Class Antifungals; Antineoplastics; Antiseptics; Antivirals; Eye disorder therapies; Quaternary ammonium compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
- Preclinical Basal cell cancer
- No development reported Onychomycosis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Onychomycosis in USA (Topical)
- 12 Jul 2022 Preclinical trials in Basal cell cancer in USA (unspecified route), prior to July 2022
- 12 Jul 2022 Pharmacodynamics data from preclinical trials in Basal cell cancer released by Turn Therapeutics